report
success
treatment
lifethreaten
infect
earli
open
antibiot
era
stimul
widespread
use
second
world
war
impress
industri
effort
develop
produc
antibiot
major
progress
histori
medicin
nowaday
compromis
univers
spread
antibiot
resist
larg
escap
hospit
project
human
race
postantibiot
era
look
back
incred
saga
emphas
antibiot
resist
describ
parallel
first
antibiot
use
direct
link
exposur
resist
recogn
late
review
focu
sever
ill
patient
signific
progress
organ
support
well
diagnost
therapeut
strategi
markedli
increas
risk
develop
hospitalacquir
infect
hai
current
icu
confront
challeng
multidrugresist
organ
mdr
antimicrobi
multidrug
resist
mdr
preval
world
extrem
drug
resist
xdr
pandrug
resist
pdr
encount
increasingli
often
especi
among
hai
occur
larg
highli
special
hospit
treat
patient
emerg
antimicrobi
resist
larg
attribut
indiscrimin
abus
use
antimicrobi
societi
particularli
healthcar
set
increas
spread
resist
gene
bacteria
resist
bacteria
peopl
environ
even
area
hitherto
known
minor
resist
problem
hospit
patient
given
day
harbor
extendedspectrum
esbl
produc
enterobacteriacea
gut
flora
seen
recent
french
studi
conduct
icu
number
differ
resist
mechan
microorgan
becom
resist
agent
increas
varieti
resist
gene
increas
number
clone
within
speci
carri
resist
increas
number
differ
speci
harbor
resist
gene
increas
lead
acceler
develop
resist
enhanc
fact
resist
gene
higher
probabl
one
end
socal
success
clone
except
abil
spread
infect
caus
diseas
happen
world
face
major
outbreak
epidem
antimicrobi
resist
sometim
local
occur
outbreak
staphylococcu
aureu
escherichia
coli
klebsiella
pneumonia
acinetobact
baumannii
pseudomona
aeruginosa
enterococcu
faecali
e
faecium
latter
speci
difficult
treat
glycopeptid
resist
highli
special
healthcar
set
neonat
ward
icu
hematolog
ward
transplant
unit
aforement
bacteria
major
problem
evolv
usa
outbreak
occur
transplant
unit
east
coast
israel
greec
later
itali
today
smaller
larger
outbreak
multidrugresist
e
coli
k
pneumonia
seen
world
recent
sever
clone
also
show
resist
last
resort
agent
like
colistin
make
situat
desper
area
hospit
patient
sinc
influx
truli
new
antimicrobi
agent
limit
evid
revers
antimicrobi
resist
futur
look
grim
anoth
sign
desper
increas
interest
tri
redevelop
old
antimicrobi
method
clinic
microbiolog
speci
identif
antimicrobi
suscept
test
ast
recent
improv
dramat
consequ
today
possibl
clinic
microbiolog
laboratori
drastic
improv
turnaround
time
time
use
laboratori
receiv
process
make
avail
report
time
flight
mass
spectrometri
brought
time
requir
speci
identif
h
day
sometim
sever
day
bacteria
fungi
blood
cultur
often
posit
within
h
start
incub
novel
techniqu
speci
identif
feasibl
directli
posit
blood
cultur
bottl
within
h
posit
blood
cultur
signal
time
wast
transport
blood
cultur
bottl
becom
import
ideal
bottl
incub
within
h
inocul
time
exce
h
constitut
malpractic
ast
perform
use
tradit
method
phenotyp
antimicrobi
suscept
test
base
minimum
inhibitori
concentr
mic
antibiot
applic
breakpoint
categor
isol
suscept
intermedi
resist
r
ast
also
perform
use
genotyp
method
commonli
form
direct
gene
detect
use
polymeras
chain
reaction
method
detect
specif
resist
gene
meca
gene
encod
methicillinresist
staphylococci
vana
gene
encod
glycopeptid
resist
enterococci
staphylococci
research
commun
current
explor
use
whole
genom
sequenc
ast
advantag
phenotyp
method
quantifi
predict
sensit
resist
phenotyp
method
mic
disk
diffus
tradit
need
h
classic
overnight
incub
howev
incub
time
tradit
system
recalibr
brought
h
depend
microorgan
resist
mechan
advantag
genotyp
method
rapid
specif
far
predict
resist
quantit
intern
agreement
standard
method
determin
mic
breakpoint
still
one
system
europ
mani
year
seven
system
use
includ
clinic
laboratori
standard
institut
clsi
system
usa
european
committe
antimicrobi
suscept
test
eucast
manag
period
unit
six
european
nation
system
harmon
system
breakpoint
europ
sinc
mani
noneuropean
countri
join
eucast
eucast
clsi
breakpoint
avail
intern
use
suscept
test
method
eucast
recommend
freeli
avail
internet
wherea
clsi
recommend
must
purchas
gener
rule
clinic
breakpoint
eucast
somewhat
lower
clsi
breakpoint
mainli
eucast
breakpoint
systemat
revis
basi
recent
inform
wherea
mani
breakpoint
clsi
neither
review
revis
year
target
educ
provid
assist
optim
choic
dosag
durat
antibiot
improv
outcom
reduc
develop
resist
antibiot
stewardship
program
critic
ill
patient
translat
implement
specif
guidelin
larg
promot
surviv
sepsi
campaign
earli
adequ
antibiot
treatment
significantli
improv
outcom
critic
ill
patient
suffer
sever
infect
howev
earli
start
antibiot
decreas
proport
microbiolog
document
mandatori
success
subsequ
deescal
adequ
coverag
potenti
resist
microorgan
result
viciou
circl
character
progress
enlarg
spectrum
cover
fig
concept
antibiot
stewardship
progress
evolv
individu
prescript
introduct
new
concept
avoid
unnecessari
administr
broadspectrum
antibiot
systemat
deescal
demonstr
posit
impact
critic
ill
set
systemat
review
show
despit
rel
low
level
studi
publish
includ
three
random
prospect
studi
three
interrupt
time
seri
antibiot
stewardship
gener
benefici
strategi
shown
reduct
use
antimicrobi
defin
daili
dose
lower
antimicrobi
cost
us
per
patient
day
shorter
averag
durat
treatment
less
inappropri
use
fewer
advers
event
intervent
beyond
month
result
reduct
rate
antimicrobi
resist
importantli
antibiot
stewardship
associ
increas
nosocomi
infect
rate
length
stay
mortal
moreov
context
high
endem
methicillinresist
aureu
mrsa
antibiot
stewardship
combin
improv
infect
control
measur
achiev
sustain
reduct
rate
hospitalacquir
mrsa
bacteremia
accordingli
strongli
recommend
icu
expert
support
sever
nation
intern
initi
antibiot
stewardship
program
develop
implement
everi
icu
institut
charg
critic
ill
patient
tabl
inappropri
antimicrobi
therapi
mean
select
antibiot
caus
pathogen
resist
consist
predictor
poor
outcom
septic
patient
hand
sever
studi
shown
prompt
appropri
antimicrobi
treatment
lifesav
approach
manag
sever
sepsi
concept
adequ
antimicrobi
therapi
defin
extens
appropri
antimicrobi
therapi
mean
appropri
earli
therapi
optim
dose
dose
interv
impress
data
probabl
come
kumar
et
al
show
inadequ
initi
antimicrobi
therapi
septic
shock
associ
fivefold
reduct
surviv
vs
remain
highli
associ
risk
death
even
adjust
potenti
risk
factor
odd
ratioor
differ
surviv
seen
major
epidemiolog
clinic
organ
subgroup
rang
pneumococc
infect
primari
bacteremia
obvious
mean
sever
infect
antimicrobi
therapi
must
almost
alway
empir
isol
identif
caus
organ
determin
organ
sensit
achiev
time
initi
unfortun
rise
incid
mdr
microorgan
lead
least
one
two
consequ
increas
incid
inappropri
antimicrobi
therapi
higher
consumpt
broadspectrum
antibiot
way
viciou
spiral
assum
best
antibiot
select
choic
antibiot
best
possibl
combin
high
effect
infect
cure
relaps
avoid
one
hand
low
collater
damag
recent
multicent
studi
hospitalacquir
bacteremia
incid
mdr
xdr
microorgan
respect
multivari
model
mdr
isol
time
adequ
treatment
independ
predictor
mortal
occur
commun
rise
preval
mdr
bacteria
instanc
among
patient
communityacquir
pneumonia
admit
icu
spain
uk
therefor
evid
infect
mdr
bacteria
often
result
delay
appropri
antibiot
therapi
result
increas
patient
morbid
mortal
well
prolong
hospit
stay
convers
also
proof
appropri
initi
antibiot
therapi
earli
icu
admiss
maxim
microbiolog
document
modifi
processofcar
factor
contribut
improv
outcom
help
reduc
antibiot
treatment
durat
promis
paramet
appear
plasma
level
procalcitonin
pct
besid
pct
sepsi
biomark
achiev
univers
use
throughout
differ
healthcar
set
last
decad
high
pct
concentr
typic
found
bacteri
infect
contrast
lower
level
viral
infect
level
ngml
patient
without
infect
furthermor
serum
pct
concentr
posit
correl
sever
infect
thu
adequ
antibiot
treatment
lead
decreas
serum
pct
concentr
recent
metanalysi
show
signific
reduct
length
antibiot
therapi
favor
pctguid
therapi
strategi
basic
two
reason
favor
antibiot
combin
therapi
monotherapi
firstli
potenti
synergi
combin
antibiot
order
maxim
clinic
efficaci
prevent
develop
resist
synergist
effect
howev
proven
vitro
mani
combin
antibiot
clear
benefit
demonstr
vivo
treatment
invas
pneumococc
diseas
toxic
shock
syndrom
two
clinic
situat
combin
macrolid
lincosamid
respect
abl
inhibit
bacteri
pathogen
factor
associ
improv
surviv
second
reason
select
combin
therapi
desir
extens
expect
spectrum
pathogen
socal
gap
close
howev
none
random
control
trial
rct
patient
sepsi
could
demonstr
advantag
combin
therapi
metaanalysi
rct
compar
combin
therapi
plu
aminoglycosid
versu
monotherapi
betalactam
alon
show
benefit
combin
therapi
term
morbid
mortal
similarli
subgroup
analysi
septic
patient
canadian
ventilatorassoci
pneumonia
vap
studi
compar
meropenem
monotherapi
meropenemciprofloxacin
combin
therapi
also
found
differ
morbid
mortal
advers
reaction
group
final
maxsept
studi
german
studi
group
compet
network
sepsi
sepnet
compar
meropenem
meropenemmoxifloxacin
combin
sever
sepsi
septic
shock
could
demonstr
differ
group
either
chang
sofa
score
mortal
result
favor
combin
therapi
found
cohort
studi
benefit
combin
therapi
shown
term
lower
mortal
especi
patient
septic
shock
drawback
studi
variou
variou
combin
partner
chosen
import
differ
observ
studi
rct
mention
former
conduct
countri
significantli
higher
rate
mdr
pathogen
latter
canadian
maxsept
studi
mention
resist
pathogen
found
less
case
suggest
combin
therapi
may
ration
result
anticip
resist
pattern
treatment
failur
monotherapi
like
sever
observ
studi
look
carbapenemresist
cr
pathogen
demonstr
surviv
benefit
combin
therapi
use
carbapenem
togeth
colistin
andor
tigecyclin
comparison
meropenem
alon
addit
intraven
fosfomycin
recent
administ
part
combin
regimen
patient
xdr
k
pneumonia
infect
improv
effect
decreas
rate
emerg
resist
also
aminoglycosid
recent
use
combin
regimen
patient
difficulttotreat
infect
includ
xdr
k
pneumonia
infect
conclus
combin
therapi
recommend
patient
sever
sepsi
infect
resist
organ
like
deescal
effect
monotherapi
consid
antibiogram
avail
deescal
antimicrobi
therapi
often
advoc
integr
part
antibiot
stewardship
program
defin
reduc
number
antibiot
treat
infect
well
narrow
spectrum
antimicrobi
agent
essenti
strategi
applic
start
broadspectrum
empir
therapi
prior
identif
caus
pathogen
intuit
would
limit
applic
deescal
concept
mdr
infect
identif
mdr
pathogen
often
antimicrobi
requir
depend
pathogen
involv
even
multipl
antibiot
may
requir
even
antibiot
class
combin
therapi
ertapenem
anoth
carbapenem
k
pneumonia
carbapenemas
kpc
produc
surprisingli
sever
clinic
studi
found
presenc
mdr
pathogen
motiv
deescal
even
situat
patient
colon
mdr
organ
site
infect
site
studi
report
deescal
safe
mdrcolon
patient
howev
mean
concept
deescal
applic
mdr
infect
depend
antibiot
suscept
antimicrobi
agent
narrow
spectrum
may
avail
combin
therapi
may
stop
initi
therapi
infect
resolv
deescal
may
prove
valid
option
order
avoid
antibiot
pressur
howev
valu
deescal
set
mdr
infect
extens
explor
applic
consid
individu
patient
basi
retrospect
analys
found
deescal
safe
approach
appli
select
patient
recent
nonblind
rct
deescal
patient
superinfect
increas
antibiot
use
although
intuit
logic
frequent
suggest
deescal
antibiot
therapi
clearli
associ
lower
rate
antibiot
resist
develop
known
antimicrobi
resist
defin
clinic
laboratori
often
translat
insuffici
vivo
exposur
result
poor
clinic
econom
outcom
addit
resist
becom
increasingli
recogn
host
respons
infect
may
contribut
consider
reduct
antimicrobi
exposur
due
alter
cardiovascular
renal
hepat
pulmonari
system
recent
icu
studi
highlight
potenti
impact
adapt
renal
system
critic
ill
patient
manifest
augment
renal
function
defin
creatinin
clearanc
initi
week
hospit
find
particularli
concern
backbon
antimicrobi
regimen
icu
penicillin
cephalosporin
carbapenem
predominantli
clear
via
renal
rout
end
robert
colleagu
recent
report
result
prospect
multin
pharmacokinet
studi
assess
exposur
critic
ill
popul
studi
investig
note
among
infect
patient
achiev
adequ
antimicrobi
exposur
patient
less
like
satisfactori
infect
outcom
person
approach
dose
base
given
patient
specif
pharmacokinet
profil
yet
standard
practic
might
expect
aminoglycosid
vancomycin
due
lack
routin
avail
drug
assay
pharmacokinet
pharmacodynam
pkpd
profil
well
agent
may
incorpor
treatment
algorithm
optim
outcom
end
develop
implement
pharmacodynam
optim
regimen
incorpor
use
higher
dose
well
prolong
continu
infus
administr
techniqu
enhanc
vivo
exposur
patient
vap
util
regimen
shown
improv
clinic
microbiolog
econom
outcom
associ
icu
base
infect
clinician
need
recogn
earli
stage
infect
alter
metabol
pathway
well
reduc
suscept
target
pathogen
may
result
inadequ
antimicrobi
exposur
convent
dose
regimen
util
therefor
pharmacodynam
optim
dose
regimen
given
patient
empir
pathogen
suscept
clinic
respons
known
local
stewardship
practic
may
employ
redefin
appropri
regimen
patient
depend
icu
set
onethird
half
patient
may
develop
nosocomi
infect
unfortun
host
suscept
infect
slightli
modifi
presenc
microorgan
high
densiti
care
unavoid
consequ
prevent
infect
dissemin
reli
elimin
mean
transmiss
use
infect
control
measur
global
idea
isol
precaut
combin
systemat
use
standard
precaut
hand
hygien
glove
gown
eye
protect
transmissionbas
precaut
contact
droplet
airborn
tabl
conceptu
object
isol
prevent
transmiss
microorgan
anticip
potenti
rout
transmiss
measur
appli
action
care
physic
contact
main
rout
transmiss
major
bacteria
howev
seem
true
certain
bacteria
name
mrsa
demonstr
recent
studi
occur
via
hand
healthcar
worker
hcw
patient
contamin
surfacesinstru
nearbi
anoth
patient
process
care
hand
hygien
hand
wash
alcohol
handrub
patient
wash
surfac
cleans
effici
reduc
transmiss
transmiss
occur
via
droplet
airborn
particl
specif
transmissionbas
precaut
requir
avoid
infect
summar
tabl
isol
precaut
wide
diffus
nowaday
cornerston
prevent
measur
use
control
outbreak
decreas
rate
resist
microorgan
mrsa
esbl
spread
emerg
infecti
diseas
respiratori
virus
sar
influenza
corona
viru
viral
hemorrhag
fever
context
enhanc
adher
appropri
isol
precaut
markedli
decreas
resist
dissemin
potenti
need
broadspectrum
antibiot
select
decontamin
digest
tract
sdd
propos
prevent
endogen
exogen
infect
reduc
mortal
critic
ill
patient
although
efficaci
sdd
confirm
rct
systemat
review
sdd
subject
intens
controversi
base
mainli
insuffici
evid
efficaci
concern
resist
recent
metaanalysi
detect
relat
use
sdd
develop
antimicrobi
resist
suggest
perceiv
risk
longterm
harm
relat
select
decontamin
justifi
avail
data
howev
conclus
studi
indic
effect
decontamin
iculevel
antimicrobi
resist
rate
understudi
although
sdd
provid
shortterm
benefit
neither
longterm
impact
control
emerg
resist
outbreak
set
high
resist
rate
maintain
use
approach
era
carbapenem
resist
antimicrobi
colistin
aminoglycosid
often
repres
last
option
treat
multidrugresist
gramneg
infect
set
use
colistin
care
consid
possibl
avoid
outbreak
due
resist
gramneg
bacilli
antibiot
pipelin
continu
diminish
major
public
remain
unawar
critic
situat
caus
declin
antibiot
develop
multifactori
drug
develop
gener
face
increas
challeng
given
high
cost
requir
current
estim
rang
us
million
per
approv
agent
furthermor
antibiot
lower
rel
rate
return
invest
drug
usual
use
shortcours
therapi
contrast
chronic
diseas
includ
hiv
hepat
requir
longterm
mayb
lifelong
treatment
suppress
symptom
repres
ration
opportun
invest
pharmaceut
industri
iron
antibiot
victim
success
less
desir
drug
compani
success
drug
numer
agenc
profession
societi
highlight
problem
lack
new
antibiot
especi
mdr
gramneg
pathogen
sinc
repeat
call
reinvigor
pharmaceut
invest
antibiot
research
develop
made
infecti
diseas
societi
america
idsa
sever
notabl
societi
includ
innov
medicin
initi
europ
largest
initi
fund
combact
idsa
support
program
call
initi
aim
develop
ten
new
system
antibacteri
drug
discoveri
new
drug
class
new
molecul
alreadi
exist
class
antibiot
current
assess
pipelin
last
updat
august
show
new
antibiot
develop
recent
approv
tabl
phase
clinic
trial
phase
seven
phase
new
drug
applic
submit
one
three
recent
approv
five
seven
antibiot
phase
well
one
drug
submit
review
us
food
drug
administr
fda
potenti
address
infect
caus
mdr
gramneg
pathogen
press
unmet
need
unfortun
limit
new
option
gramneg
bacteria
carbapenemaseproduc
enterobacteriacea
xdr
baumannii
p
aeruginosa
aerosol
administr
drug
seem
promis
new
approach
treatment
mdr
lung
infect
nebul
antibiot
achiev
good
lung
concentr
reduc
risk
toxic
compar
intraven
administr
new
vibrat
mesh
nebul
use
deliv
amikacin
achiev
high
concentr
lower
respiratori
tract
tenfold
higher
concentr
bacteria
normal
respons
nosocomi
lung
infect
p
aeruginosa
document
epitheli
line
fluid
amikacin
infect
caus
extendedspectrum
esblp
difficult
treat
owe
resist
organ
mani
antibiot
sinc
eucast
clsi
recommend
use
altern
carbapenem
treat
organ
inde
basi
antimicrobi
suscept
test
inhibitor
blbli
specif
fourthgener
cephalosporin
ie
cefepim
greater
stabil
could
theoret
use
treat
esblp
infect
far
know
altern
carbapenem
evalu
critic
ill
patient
outsid
icu
data
still
scarc
conflict
post
hoc
analysi
patient
bloodstream
infect
due
esbl
coli
six
publish
prospect
cohort
suggest
blbli
includ
acid
suitabl
altern
carbapenem
metaanalysi
vardaka
et
al
compar
carbapenem
blbli
bacteremia
caus
esblproduc
organ
take
account
consider
heterogen
trial
includ
fact
none
power
detect
outcom
differ
fact
sever
ill
patient
tend
receiv
carbapenem
statist
signific
differ
mortal
patient
receiv
empir
definit
therapi
blbli
carbapenem
regard
use
cefepim
specif
situat
data
avail
confus
seem
use
safe
case
infect
isol
mic
valu
mgl
less
critic
ill
patient
dosag
g
everi
h
higher
probabl
prefer
suggest
recent
studi
specif
situat
practition
awar
risk
suboptim
dosag
accord
recent
data
critic
ill
patient
carbapenem
still
prefer
altern
empir
therapi
esblp
suspect
altern
definit
therapi
could
possibl
suscept
known
howev
high
dosag
semicontinu
administr
prefer
vast
major
cre
isol
resist
clinic
reliabl
antibiot
class
leav
colistin
tigecyclin
gentamicin
main
therapeut
approach
wherea
sever
report
reveal
high
risk
mortal
associ
infect
given
lack
data
random
clinic
trial
therapeut
approach
cre
infect
base
accumul
clinic
experi
particularli
infect
k
pneumonia
produc
either
kpc
verona
integronmedi
vim
recent
evid
support
combin
treatment
contain
two
three
vitro
activ
drug
reveal
signific
advantag
monotherapi
term
surviv
although
paradox
sinc
kpc
enzym
hydrolys
carbapenem
signific
improv
seem
obtain
combin
includ
carbapenem
provid
substanti
surviv
benefit
patient
sever
ill
andor
septic
shock
carbapenem
vivo
activ
cre
compat
mic
reach
mgl
probabl
attribut
enhanc
drug
exposur
highdoseprolongedinfus
regimen
carbapenem
aminoglycosidecontain
combin
particularli
gentamicin
associ
favor
outcom
compar
combin
could
serv
backbon
particularli
view
increas
rate
colistin
resist
colistin
tigecyclin
repres
remain
agent
select
combin
base
sensit
pattern
recent
report
clinic
success
treatment
infect
xdr
pdr
pathogen
combin
fosfomycin
make
anoth
therapeut
candid
particularli
treatment
enterobacteriacea
suscept
rate
promis
high
dose
gday
avoid
monotherapi
strongli
recommend
set
critic
ill
patient
mdr
pathogen
fail
monotherapi
colistin
tigecyclin
may
explain
suboptim
exposur
drug
recent
pkpd
data
favor
dose
escal
compar
initi
recommend
dose
regimen
small
singlecent
noncompar
studi
employ
load
dose
ld
miu
follow
miu
bid
adapt
accord
renal
function
show
colistin
monotherapi
might
adequ
concis
guid
optim
use
polymyxin
shown
electron
supplementari
materi
higher
dose
mgday
may
optim
tigecyclin
pk
result
improv
clinic
outcom
doubl
carbapenem
combin
consist
ertapenem
substrat
doripenem
meropenem
activ
compound
recent
proven
success
case
seri
small
studi
even
pathogen
express
high
mic
carbapenem
final
decis
regard
empir
antibiot
treatment
critic
ill
patient
must
base
sound
knowledg
local
distribut
pathogen
analysi
presenc
risk
factor
infect
caus
cre
p
aeruginosa
along
e
coli
k
pneumonia
baumannii
lead
pathogen
icu
set
caus
sever
infect
vap
bacteremia
mortal
directli
relat
delay
start
appropri
antibiot
therapi
high
percentag
p
aeruginosa
isol
resist
aminoglycosid
ceftazidim
fluoroquinolon
piperacillintazobactam
carbapenem
report
sever
countri
especi
southern
eastern
europ
resist
carbapenem
countri
report
european
center
diseas
control
ecdc
mdr
also
common
isol
report
resist
least
three
antimicrobi
class
crresist
p
aeruginosa
account
isol
italian
icu
strain
also
resist
colistin
primari
regimen
suscept
isol
depend
site
sever
infect
summar
tabl
betalactam
antibiot
antipseudomona
activ
gener
prefer
administ
extend
infus
ld
rapidli
achiev
pharmacodynam
target
although
clear
evid
support
advantag
combin
therapi
ie
plu
aminoglycosid
fluoroquinolon
monotherapi
mani
clinician
adopt
regimen
seriou
infect
bacteremia
vap
patient
sever
sepsi
septic
shock
combin
therapi
aminoglycosid
amikacin
gentamicin
prefer
recommend
maximum
durat
day
infect
caus
strain
suscept
colistin
regimen
highdos
colistin
mu
ld
mu
bid
recommend
nebul
administr
colistin
also
consid
vap
intrathec
administr
requir
mening
advantag
ad
carbapenem
case
noncarbapenemsuscept
strain
colistin
unclear
sever
expert
prefer
use
combin
show
synergist
activ
vitro
ie
colistin
plu
rifampin
fosfomycin
show
variabl
vitro
activ
p
aeruginosa
mdrxdr
strain
may
administ
mainli
part
combin
regimen
system
infect
g
everi
h
new
drug
activ
p
aeruginosa
includ
ceftazidimeavibactam
nonlactam
inhibitor
class
c
ampc
p
aeruginosa
new
aminoglycosid
plazomicin
combin
new
cephalosporin
ceftolozan
tazobactam
show
activ
also
mdr
xdr
p
aeruginosa
strain
complet
phase
trial
treatment
complic
intraabdomin
infect
ciai
complic
urinari
tract
infect
cuti
baumannii
gain
increas
attent
potenti
caus
sever
infect
abil
develop
resist
practic
avail
antimicrobi
adequ
empir
therapi
sever
infect
caus
baumannii
crucial
term
surviv
empir
treatment
baumannii
infect
often
repres
challeng
might
consid
case
sever
sepsissept
shock
center
greater
preval
mdr
baumannii
tradit
carbapenem
drug
choic
still
prefer
antimicrobi
acinetobact
infect
area
high
rate
suscept
sulbactam
bactericid
baumannii
repres
suitabl
altern
baumannii
suscept
agent
unfortun
steadi
increas
resist
sulbactam
baumannii
observ
nowaday
polymyxin
antimicrobi
greatest
level
vitro
activ
baumannii
howev
indiscrimin
use
may
contribut
select
resist
may
also
expos
patient
unnecessari
toxic
thu
select
patient
receiv
empir
treatment
cover
acinetobact
essenti
colistin
wide
use
clinic
practic
although
polymyxin
b
seem
associ
less
renal
toxic
recommend
dose
antimicrobi
shown
tabl
tigecyclin
activ
vitro
wide
rang
gramneg
bacilli
includ
baumannii
approv
europ
treatment
complic
skin
structur
infect
intraabdomin
infect
nevertheless
although
divers
metaanalys
warn
increas
risk
death
patient
receiv
tigecyclin
compar
antibiot
particularli
hap
vap
high
dose
regimen
tabl
usual
combin
anoth
antimicrobi
may
valid
altern
sever
infect
includ
baumannii
pneumonia
although
vitro
studi
demonstr
synergi
colistin
rifampin
recent
rct
demonstr
improv
clinic
outcom
combin
colistinrifampin
better
erad
achiev
differ
vitro
studi
document
exist
unforeseen
potent
synerg
combin
colistin
glycopeptid
carbapenemresist
baumannii
howev
combin
colistin
plu
glycopeptid
baumannii
infect
actual
discourag
main
treatment
option
treat
mrsa
infect
critic
ill
patient
includ
glycopeptid
vancomycin
teicoplanin
linezolid
daptomycin
daptomycin
contraind
treatment
pneumonia
inactiv
surfact
altern
antimrsa
agent
tigecyclin
regulatori
warn
concern
possibl
small
increas
unexplain
mortal
risk
telavancin
associ
warn
contraind
use
notabl
patient
renal
failur
ceftarolin
dalbavancin
oritavancin
limit
evid
efficaci
sever
infect
numer
metaanalys
compar
efficaci
aforement
agent
mrsa
infect
four
metaanalys
unusu
assess
possibl
treatment
option
although
one
studi
examin
mrsa
infect
type
oppos
mrsa
cssti
latter
network
metaanalysi
studi
identifi
rct
cssti
hapvap
compar
one
six
antibiot
vancomycin
cssti
linezolid
ceftarolin
nonsignificantli
effect
vancomycin
linezolid
or
ceftarolin
or
modifi
intent
treat
mitt
mrsa
mmitt
popul
respect
hapvap
linezolid
nonsignificantli
better
vancomycin
or
mitt
mrsa
mmitt
popul
respect
data
zephyr
trial
suggest
clinic
superior
linezolid
compar
vancomycin
higher
rate
success
clinic
respons
accept
safeti
toler
profil
treatment
proven
mrsa
nosocomi
pneumonia
microbiolog
respons
parallel
clinic
outcom
mrsa
clearanc
greater
linezolid
vancomycin
differ
least
persist
late
followup
suggest
linezolid
treatment
may
result
complet
bacteri
erad
uncertainti
surround
rel
efficaci
vancomycin
fuell
report
wors
outcom
patient
mrsa
infect
caus
strain
elev
mic
recent
metaanalysi
aureu
bacteremia
studi
fail
find
overal
increas
risk
death
compar
case
caus
aureu
exhibit
highvancomycin
mic
least
mgl
due
lowvancomycin
mic
less
mgl
strain
outbreak
mrsa
resist
linezolid
mediat
cfr
gene
report
associ
nosocomi
transmiss
extens
usag
linezolid
howev
author
caution
definit
exclud
increas
mortal
risk
emphas
point
remain
possibl
specif
mrsa
strainsclon
associ
wors
outcom
attempt
address
elev
mic
improv
target
attain
increas
vancomycin
dosag
associ
nephrotox
sever
c
difficil
infect
cdi
character
least
one
follow
white
blood
cell
count
greater
acut
rise
serum
creatinin
ie
greater
increas
baselin
temperatur
greater
abdomin
radiolog
evid
sever
coliti
current
two
main
treatment
option
sever
cdi
either
oral
vancomycin
mg
qd
day
fidaxomicin
consid
patient
sever
cdi
high
risk
recurr
latter
includ
elderli
patient
multipl
comorbid
receiv
concomit
antibiot
metronidazol
monotherapi
avoid
patient
sever
cdi
increas
evid
inferior
altern
discuss
sever
cdi
case
respond
oral
vancomycin
mg
qd
oral
fidaxomicin
mg
bid
altern
highdosag
oral
vancomycin
mg
qd
necessari
administ
via
nasogastr
tube
without
iv
metronidazol
mg
td
addit
oral
rifampicin
mg
bid
iv
immunoglobulin
mgkg
may
also
consid
evid
lack
regard
efficaci
approach
case
report
tigecyclin
use
treat
sever
cdi
fail
respond
convent
treatment
option
unlicens
indic
lifethreaten
cdi
ie
hypotens
partial
complet
ileu
toxic
megacolon
oral
vancomycin
mg
qid
day
via
nasogastr
tube
clamp
h
andor
rectal
instal
vancomycin
enema
plu
iv
metronidazol
mg
three
time
daili
use
poor
evid
base
case
patient
requir
close
monitor
specialist
surgic
input
blood
lactat
measur
colectomi
consid
caecal
dilat
cm
case
perfor
septic
shock
colectomi
best
perform
blood
lactat
rise
mmoll
surviv
extrem
poor
recent
systemat
review
conclud
total
colectomi
end
ileostomi
prefer
surgic
procedur
procedur
associ
high
rate
reoper
mortal
less
extens
surgeri
may
role
select
patient
earlierstag
diseas
altern
approach
divert
loop
ileostomi
colon
lavag
report
associ
reduc
morbid
mortal
current
clinic
practic
relat
critic
ill
patient
extrem
challeng
emerg
multidrug
resist
among
commonli
encount
pathogen
treatment
option
seem
optimist
gramposit
pathogen
includ
c
difficil
pipelin
promis
howev
recent
launch
antimrsa
agent
extens
investig
critic
ill
popul
field
gramneg
mdr
infect
great
concern
therapeut
futur
hand
upcom
agent
address
unmet
medic
need
associ
betalactam
betalactamas
inhibitor
seem
promis
gramneg
mdr
pathogen
real
clinic
util
known
result
larg
clinic
trial
avail
current
effect
approach
pkpd
optim
avail
antibiot
particularli
given
increas
awar
pharmacokinet
alter
occur
critic
ill
patient
combin
treatment
seem
import
least
empir
phase
treatment
ensur
adequ
coverag
patient
improv
clinic
outcom
howev
random
clinic
trial
urgent
need
defin
possibl
benefit
combin
variou
set
importantli
infect
control
measur
prompt
diagnost
cornerston
prevent
transmiss
mdr
xdr
pathogen
healthcar
set
optim
earli
antimicrobi
treatment
